To the Editor.—
This letter is in reply to the letter by Weiner and Nausieda (Archives 1981;38:534) concerning our article published in the Archives (1980;37:723-726). Drs Weiner and Nausieda stated that our "study of the use of an increased ratio of carbidopa to levodopa in the treatment of Parkinson's disease is rather difficult to interpret." They also raised some specific questions regarding the study and some general issues regarding the treatment of Parkinson's disease. We will address these in the order they were presented in their letter.Weiner and Nausieda stated, "The response of the patients to these three different treatment regimens after a two-week period was used to conclude that increasing the amount of carbidopa in presently available drugs is a desirable treatment modality." In fact, we concluded that "increasing the amount of carbidopa from 10 to 20 mg per 100-mg dose of levodopa gives a greater therapeutic response
Tourtellotte WW, Syndulko K, Potvin AR. Carbidopa-Levodopa Ratio in Parkinson's Disease. Arch Neurol. 1981;38(11):737–738. doi:10.1001/archneur.1981.00510110097024
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: